Democracy unleashed - Unpacking the tooth fairy in drug industry R and D [3]

Nature Biotechnology

Volumn 24, Issue 11, 2006, Pages 1324-1326

  Ozdemir, Vural ^a   Williams Jones, Bryn ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT;

BIOTECHNOLOGY; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DEVELOPING COUNTRY; DRUG COST; DRUG INDUSTRY; DRUG RESEARCH; DRUG SAFETY; ECONOMIC ASPECT; FINANCIAL MANAGEMENT; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH PROMOTION; LETTER; MEDICAL ETHICS; MEDICAL PRACTICE; PHARMACEUTICAL ENGINEERING; PHARMACOEPIDEMIOLOGY; PHARMACOPHORE; POLITICAL SYSTEM; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; SOCIAL BEHAVIOR; STATISTICAL SIGNIFICANCE; SUSTAINABLE DEVELOPMENT; TROPICAL DISEASE; UNITED STATES;

BIOTECHNOLOGY; DRUG COSTS; DRUG INDUSTRY; HEALTH SERVICES ACCESSIBILITY; HUMANS; POLICY MAKING; PUBLIC HEALTH; PUBLIC OPINION; PUBLIC POLICY; RESEARCH; SOCIAL JUSTICE; UNITED STATES;

EID: 33750867254     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt1106-1324     Document Type: Letter

References (21)

1. Angell, M. The Truth About the Drug Companies: How They Deceive Us and What to Do About It (New York, Random House, 2004).
2. Wilson, D.S. in The Literary Animal: Evolution and the Nature of Narrative (eds., Gottschall, J. & Wilson, D.S.) 20-37 (Northwestern University Press, Evanston, Illinois, 2005)
3. Turner, E.H. PLoS Med.1, e60 (2004).
4. Graham, J.E. Can. Med. Assoc. J. 173, 1469-1470 (2005).
5. Lexchin, J. Can. Med. Assoc. J. 172, 765-767 (2005).
6. Brennan, T.A. et al. J. Am. Med. Assoc. 295, 429-433 (2006).
7. Mintzes, B. & Lexchin, J. Can. J. Clin. Pharmacol. 12, 22-27 (2005).
8. Lazarou, J., Pomeranz, B.H. & Corey, P.N. J. Am. Med. Assoc. 279, 1200-1205 (1998).
9. Sheiner, L.B. Clin. Pharmacol. Ther. 46, 605-615 (1989).
10. Sheiner, L.B. Clin. Pharmacol. Ther. 50, 4-9 (1991).
11. Sheiner, L.B. Clin. Pharmacol. Ther. 61, 275-291 (1997).
12. Trouiller, P. et al. Lancet. 359, 2188-2194 (2002).
13. http://www.fda.gov/cder/rdmt/pstable.htm
14. DiMasi, J.A., Hansen, R.W. & Grabowski, H.G. J. Health Econ. 22, 151-185 (2003).
15. Angell, M. Can. Med. Assoc. J. 171, 1451-1453 (2004).
16. Light, D.W. & Warburton, R.N. J. Health Econ. 24, 1030-1033 (2005).
17. Kerber, R. Drug makers target consumers with their ads. Boston Globe March 10 (2004), p. C1.
18. Corrigan, O.P. Feminist Rev. 72, 40-52 (2002).
19. Dwyer, J. Bioethics 19, 460-475 (2005).
20. Paehlke, R.C. Democracy's Dilemma: Environment, Social Equity and the Global Economy (Cambridge, The MIT Press, 2004).
21. Campbell, A.V. Genomics Soc. Policy 1, 86-91 (2005).